12:00 AM
Jul 11, 2016
 |  BC Week In Review  |  Clinical News  |  Regulatory

NGAL Test regulatory update

BioPorto said it will continue to seek FDA approval of its NGAL Test to detect acute kidney injury following discussions with the agency and anticipates “approval within...

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >